Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Wild-type

NCT00861120 is registered in ClinicalTrials.gov with Vejle Hospital as lead sponsor.

NCT NCT00861120
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00861120 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Wild-type
Lead sponsor
Vejle Hospital
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2009
Completion date
August 31, 2012
Enrollment
33 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

epithelial ovarian cancer